

# CITATION REPORT

List of articles citing

**Clinicopathological definition of Waldenstrom's  
macroglobulinemia: consensus panel  
recommendations from the Second International  
Workshop on Waldenstrom's Macroglobulinemia**

**DOI: 10.1053/sonc.2003.50082**

**Seminars in Oncology, 2003, 30, 110-5.**

**Source:** <https://exaly.com/paper-pdf/35005573/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
769	Mature B-cell leukemias. 171-190		
768	An unusual case of Waldenstrom's macroglobulinemia presented with nasopharyngeal involvement. <b>2013</b> , 7, 362		
767	Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. <i>Seminars in Oncology</i> , <b>2003</b> , 30, 127-31	5.5	74
766	Defining Waldenstrom's macroglobulinemia. <i>Seminars in Oncology</i> , <b>2003</b> , 30, 107-9	5.5	19
765	Waldenström macroglobulinaemia. <b>2003</b> , 4, 679-85		123
764	Protein precipitation as a possible important pitfall in the clinical chemistry analysis of blood samples containing monoclonal immunoglobulins: 2 case reports and a review of the literature. <b>2004</b> , 59, 263-73		52
763	Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. <b>2004</b> , 15, 1481-3		121
762	IgM AL amyloidosis due to B cell lymphoproliferative disorder: efficacy of high-dose melphalan followed by autologous stem cell transplantation. <b>2004</b> , 11, 130-5		6
761	Amyloidosis and Waldenström's macroglobulinemia. <b>2004</b> , 2004, 257-82		65
760	Use of fludarabine in the treatment of mantle cell lymphoma, Waldenström's macroglobulinemia and other uncommon B- and T-cell lymphoid malignancies. <b>2004</b> , 5 Suppl 1, S50-61		10
759	Clinical characteristics and factors predicting evolution of asymptomatic IgM monoclonal gammopathies and IgM-related disorders. <b>2004</b> , 18, 1512-7		42
758	The international staging system for multiple myeloma is applicable in symptomatic Waldenstrom's macroglobulinemia. <i>Leukemia and Lymphoma</i> , <b>2004</b> , 45, 1809-13	1.9	27
757	Treatment options in Waldenstrom's macroglobulinemia. <b>2004</b> , 5, 155-62		4
756	Clinical responses to sildenafil in Waldenstrom's macroglobulinemia. <b>2004</b> , 5, 205-7		22
755	IgM paraproteinaemic neuropathies. <b>2004</b> , 17, 599-605		49
754	Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood. <i>Blood</i> , <b>2004</b> , 104, 2134-42	2.2	80
753	Lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia: an evolving concept. <b>2005</b> , 12, 246-55		79

752	A SCID-hu in vivo model of human Waldenström macroglobulinemia. <i>Blood</i> , <b>2005</b> , 106, 1341-5	2.2	35
751	Lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia derives from an extensively hypermutated B cell that lacks ongoing somatic hypermutation. <b>2005</b> , 29, 729-34		25
750	Immunoglobulin gene analysis of mature B-cell malignancies: reconsideration of cellular origin and potential antigen involvement in pathogenesis. <b>2005</b> , 22, 327-41		25
749	Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients. <b>2005</b> , 19, 1831-4		63
748	Rarity of IgH translocations in Waldenström macroglobulinemia. <b>2005</b> , 163, 77-80		24
747	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Associated With IgM Paraprotein. <b>2005</b> , 123, 594-602		45
746	Lymphoid Neoplasms Associated With IgM Paraprotein. <b>2005</b> , 123, 200-205		81
745	Prognostic validation of the international classification of immunoglobulin M gammopathies: a survival advantage for patients with immunoglobulin M monoclonal gammopathy of undetermined significance?. <b>2005</b> , 11, 1786-90		54
744	Extended rituximab therapy in Waldenström's macroglobulinemia. <b>2005</b> , 16, 132-8		138
743	Cutaneous Waldenstrom's macroglobulinemia with "deck-chair" sign treated with cyclophosphamide. <b>2005</b> , 52, 45-7		12
742	Clinicopathologic features of Waldenstrom's macroglobulinemia and marginal zone lymphoma: are they distinct or the same entity?. <b>2005</b> , 5, 220-4		42
741	Autoantibody activity in Waldenstrom's macroglobulinemia. <b>2005</b> , 5, 225-9		46
740	Differential diagnosis of Waldenstrom's macroglobulinemia and other B-cell disorders. <b>2005</b> , 5, 235-40		23
739	Immunophenotypic and cytogenetic comparison of Waldenstrom's macroglobulinemia with splenic marginal zone lymphoma. <b>2005</b> , 5, 241-5		36
738	CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia. <b>2005</b> , 5, 246-9		57
737	Cell cycle analysis of Waldenstrom's macroglobulinemia. <b>2005</b> , 5, 250-2		4
736	Clinical characteristics and outcome of immunoglobulin M-related disorders. <b>2005</b> , 5, 261-4		23
735	Prognostic factors for transformation in asymptomatic immunoglobulin m monoclonal gammopathies. <b>2005</b> , 5, 265-9		10

734	Predictive factors for response to rituximab in Waldenstrom's macroglobulinemia. <b>2005</b> , 5, 270-2		29
733	CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia. <b>2005</b> , 5, 273-7		49
732	CD52 expression in Waldenstrom's macroglobulinemia: implications for alemtuzumab therapy and response assessment. <b>2005</b> , 5, 278-81		27
731	Early results of a phase I trial of oblimersen sodium for relapsed or refractory Waldenstrom's macroglobulinemia. <b>2005</b> , 5, 282-4		20
730	Cold agglutinin disease and cryoglobulinemia. <b>2005</b> , 5, 290-3		29
729	Phase III study of chlorambucil versus fludarabine as initial therapy for Waldenstrom's macroglobulinemia and related disorders. <b>2005</b> , 5, 294-7		13
728	Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenstrom's macroglobulinemia. <b>2005</b> , 6, 136-9		29
727	Waldenstrom's macroglobulinemia. <b>2005</b> , 18, 747-65		35
726	Diagnosis and management of Waldenstrom's macroglobulinemia. <b>2005</b> , 23, 1564-77		180
725	Diffuse large B-cell lymphoma as a second, clonally unrelated lymphoproliferative disease in a patient with IgM monoclonal gammopathy of undetermined significance (MGUS) and concomitant polycythemia vera rubra. <i>Leukemia and Lymphoma</i> , <b>2006</b> , 47, 940-3	1.9	4
724	Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. <i>Blood</i> , <b>2006</b> , 107, 3442-6	2.2	124
723	Monoclonal gammopathy of undetermined significance, Waldenstrom macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment. <b>2006</b> , 81, 693-703		152
722	Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. <b>2006</b> , 6, 380-3		98
721	CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders. <b>2006</b> , 6, 478-83		36
720	Immunoglobulin heavy chain sequence analysis in Waldenstrom's macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance. <b>2006</b> , 7, 70-2		9
719	Prognostic value of serum beta2-microglobulin in patients with Waldenstrom's macroglobulinemia requiring treatment. <b>2006</b> , 7, 205-9		18
718	Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. <b>2006</b> , 12, 845-54		59
717	Cold hemolytic syndrome. <b>2006</b> , 2006, 19-23		44

716	B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia. <i>Blood</i> , <b>2006</b> , 107, 2882-8	2.2	76
715	Impaired class switch recombination (CSR) in Waldenstrom macroglobulinemia (WM) despite apparently normal CSR machinery. <i>Blood</i> , <b>2006</b> , 107, 2920-7	2.2	27
714	Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. <i>Blood</i> , <b>2006</b> , 108, 2755-63	2.2	147
713	Dangerous small B-cell clones. <i>Blood</i> , <b>2006</b> , 108, 2520-30	2.2	318
712	Maladie de Waldenström ou macroglobulinémie. <b>2006</b> , 1, 1-10		1
711	Guidelines on the management of Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , <b>2006</b> , 132, 683-97	4.5	25
710	Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. <i>British Journal of Haematology</i> , <b>2006</b> , 133, 158-64	4.5	108
709	Nuclear BCL-10 expression is common in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia and does not correlate with p65 NF-kappaB activation. <b>2006</b> , 19, 891-8		17
708	6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. <b>2006</b> , 169, 150-3		85
707	Natural history and therapy of 66 patients with mixed cryoglobulinemia. <b>2006</b> , 81, 511-8		53
706	Waldenstrom's macroglobulinemia presenting with spinal cord compression: a case report. <b>2006</b> , 81, 955-8		6
705	Renal involvement in non-malignant IgM gammopathy. <b>2007</b> , 22, 627-30		5
704	Advances in the treatment of Waldenström's macroglobulinemia. <b>2006</b> , 6, 329-34		8
703	Characterization of familial Waldenstrom's macroglobulinemia. <b>2006</b> , 17, 488-94		136
702	Peripheral neuropathies in Waldenström's macroglobulinaemia. <b>2006</b> , 77, 224-8		67
701	Molecular characterization of Waldenstrom's macroglobulinemia reveals frequent occurrence of two B-cell clones having distinct IgH VDJ sequences. <b>2007</b> , 13, 2005-13		25
700	Bone Marrow and Peripheral Blood Stem Cell Transplantation. <b>2007</b> , 787-822		
699	Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. <b>2007</b> , 25, 3344-9		189

698	Proteomic analysis of waldenstrom macroglobulinemia. <b>2007</b> , 67, 3777-84		49
697	Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. <b>2007</b> , 13, 3320-5		160
696	Multiple Myeloma. <b>2007</b> ,		
695	The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. <i>Blood</i> , <b>2007</b> , 110, 4417-26	2.2	128
694	Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. <i>Blood</i> , <b>2007</b> , 109, 4964-72	2.2	94
693	Waldenström macroglobulinemia. <i>Blood</i> , <b>2007</b> , 109, 5096-103	2.2	150
692	Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy. <b>2007</b> , 12, 361-70		60
691	Case of mononeuritis multiplex onset with rituximab therapy for Waldenström's macroglobulinemia. <b>2007</b> , 260, 240-3		12
690	Cytogenetic aberrations in neuropathy associated with IgM monoclonal gammopathy. <b>2007</b> , 260, 124-31		3
689	Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. <i>Blood</i> , <b>2007</b> , 109, 2767-72	2.2	156
688	Novel agents in the treatment of Waldenström's macroglobulinemia. <b>2007</b> , 7 Suppl 5, S199-206		10
687	Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation. <b>2007</b> , 20, 665-80		34
686	Non-Hodgkin lymphoma. 290-310		
685	Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. <b>2007</b> , 121, 2260-6		96
684	Protein electrophoresis, immunoelectrophoresis and immunofixation electrophoresis as predictors for high-risk phenotype in familial Waldenström macroglobulinemia. <b>2008</b> , 122, 1183-8		6
683	Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. <b>2007</b> , 21, 255-65		48
682	Evidence of graft-versus-Waldenstrom's macroglobulinaemia effect after allogeneic stem cell transplantation: a single centre experience. <b>2007</b> , 40, 369-72		11
681	Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. <b>2007</b> , 21, 541-9		167

680	6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis. <i>British Journal of Haematology</i> , <b>2007</b> , 136, 80-6	4.5	85
679	Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ration of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity. <i>British Journal of Haematology</i> , <b>2007</b> , 137, 560-8	4.5	33
678	Management of cold haemolytic syndrome. <i>British Journal of Haematology</i> , <b>2007</b> , 138, 422-9	4.5	52
677	Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , <b>2007</b> , 138, 700-20	4.5	79
676	Waldenström macroglobulinaemia and IgM monoclonal gammopathy of undetermined significance: emerging understanding of a potential precursor condition. <i>British Journal of Haematology</i> , <b>2007</b> , 139, 663-71	4.5	18
675	Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. <b>2007</b> , 35, 1366-75		53
674	Prise en charge multidisciplinaire de la maladie de Waldenström ou macroglobulinémie. <b>2008</b> , 10, 425-428		
673	The incidence and survival of Waldenström's Macroglobulinaemia in South East England. <b>2008</b> , 32, 55-9		38
672	Refractory Waldenström's macroglobulinaemia responsive to 2-chlorodeoxyadenosine and mycophenolate mofetil. <b>2008</b> , 32, 1487-8		
671	CDDO-imidazole mediated inhibition of malignant cell growth in Waldenström macroglobulinemia. <b>2008</b> , 32, 1895-902		6
670	Malignant hematopoietic cell lines: in vitro models for the study of Waldenström's macroglobulinemia. <b>2008</b> , 32, 1669-73		9
669	Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia. <b>2008</b> , 67, 172-85		61
668	The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia. <i>British Journal of Haematology</i> , <b>2008</b> , 142, 775-85	4.5	18
667	Clinical relevance of soluble HLA class I molecules in Waldenstrom Macroglobulinemia. <b>2008</b> , 80, 503-9		1
666	[Progressive dysphagia of 2-years duration in a 78-year-old woman]. <b>2008</b> , 130, 149-55		
665	Clinical challenges and images in GI. Intestinal Waldenström macroglobulinemia. <b>2008</b> , 134, 920, 1276		2
664	CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia. <i>Blood</i> , <b>2008</b> , 112, 4683-9		66
663	IgM-lambda paraproteinemia with associated cutaneous lymphoplasmacytic infiltrate in a patient who meets diagnostic criteria for POEMS syndrome. <b>2008</b> , 58, 671-5		10

662	[Chromosomal abnormalities and Waldenström macroglobulinemia]. <b>2008</b> , 56, 400-6		2
661	Waldenstrom macroglobulinemia. <b>2008</b> , 270, 95-107		14
660	Indolent lymphomas other than follicular and marginal zone lymphomas. <b>2008</b> , 22, 903-40, viii		5
659	Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. <i>Haematologica</i> , <b>2008</b> , 93, 431-8	6.6	365
658	Development of EBV-associated diffuse large B-cell lymphoma in Waldenstrom macroglobulinemia and mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2008</b> , 49, 1618-9	1.9	8
657	Neurological manifestations of Waldenström macroglobulinemia. <b>2008</b> , 4, 547-56		45
656	Phenotypic evolution of Waldenstrom's macroglobulinemia to extramedullary plasmacytoma. <b>2008</b> , 26, 2408-10		9
655	Case records of the Massachusetts General Hospital. Case 39-2008. A 51-year-old woman with splenomegaly and anemia. <b>2008</b> , 359, 2707-18		8
654	The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients. <b>2008</b> , 87, 99-109		57
653	Renal lesions associated with IgM-secreting monoclonal proliferations: revisiting the disease spectrum. <b>2008</b> , 3, 1339-49		74
652	Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. <i>Leukemia and Lymphoma</i> , <b>2008</b> , 49, 1104-7	1.9	36
651	Lymphomes de la zone marginale. <b>2008</b> , 3, 1-9		1
650	Targeting NF-kappaB in Waldenstrom macroglobulinemia. <i>Blood</i> , <b>2008</b> , 111, 5068-77	2.2	92
649	Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. <i>Blood</i> , <b>2008</b> , 111, 4752-63	2.2	69
648	Critiquing cryos. <i>Blood</i> , <b>2008</b> , 111, 5267	2.2	
647	Thalidomide and rituximab in Waldenstrom macroglobulinemia. <i>Blood</i> , <b>2008</b> , 112, 4452-7	2.2	114
646	Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. <i>Blood</i> , <b>2008</b> , 112, 3052-6	2.2	127
645	Serum-free light chain elevation is associated with a shorter time to treatment in Waldenstrom's macroglobulinemia. <i>Haematologica</i> , <b>2008</b> , 93, 793-4	6.6	33



644	Chronic immune stimulation and subsequent Waldenström macroglobulinemia. <b>2008</b> , 168, 1903-9		39
643	WALDENSTRÖM MACROGLOBULINEMIA/LYMPHOPLASMACYTIC LYMPHOMA. 129-149		
642	Prognostic factors in monoclonal gammopathy of undetermined significance. <i>Haematologica</i> , <b>2008</b> , 93, 153-4	6.6	1
641	Fluorescence immunophenotypic and interphase cytogenetic characterization of nodal lymphoplasmacytic lymphoma. <b>2008</b> , 32, 1643-53		21
640	Rituximab in the treatment of non-Hodgkin's lymphoma. <b>2008</b> , 2, 619-33		19
639	IgM multiple myeloma presenting with spinal cord compression caused by a plasmacytoma: A case report. <b>2008</b> , 1, 207		5
638	Nephrotic syndrome and kidney failure due to immunocomplex-mediated renal damage in a patient with Waldenström's Macroglobulinemia: a case report. <b>2008</b> , 1, 333		3
637	Update on treatment recommendations from the Fourth International Workshop on Waldenström's Macroglobulinemia. <b>2009</b> , 27, 120-6		173
636	Dysimmune neuropathy. <b>2009</b> , 26, 67-84		5
635	Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. <b>2009</b> , 27, 250-5		129
634	Lenalidomide and rituximab in Waldenström's macroglobulinemia. <b>2009</b> , 15, 355-60		104
633	Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. <b>2009</b> , 27, 3830-5		206
632	Update on therapeutic options in Waldenström macroglobulinemia. <b>2009</b> , 82, 1-12		10
631	Nineteen-year follow-up of Waldenström's-associated neuropathy and Bing-Neel syndrome. <b>2009</b> , 39, 95-100		14
630	Survival in non-Hodgkin's lymphoma by histology and family history. <b>2009</b> , 135, 1711-6		10
629	Multiple myeloma. <b>2009</b> , 33, 7-64		59
628	Immunoglobulin M 'Flare' after rituximab-associated acute tubular necrosis in Waldenström's macroglobulinemia. <b>2009</b> , 89, 218-222		6
627	Commentary on the WHO classification of tumors of lymphoid tissues (2008): indolent B cell lymphomas. <b>2009</b> , 2, 77-81		23

626	Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia. <i>British Journal of Haematology</i> , <b>2009</b> , 145, 59-63	4.5	14
625	UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). <i>British Journal of Haematology</i> , <b>2009</b> , 147, 22-42	4.5	91
624	The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). <b>2009</b> , 23, 153-61		126
623	Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. <b>2009</b> , 23, 3-9		832
622	Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström's macroglobulinemia. <b>2009</b> , 22, 807-16		134
621	Waldenström's macroglobulinemia in a 10-year stable IgG monoclonal gammopathy of undetermined significance. <b>2009</b> , 33, 193-5		2
620	SDF1/CXCL12 (-801GA) polymorphism is a prognostic factor after treatment initiation in Waldenstrom macroglobulinemia. <b>2009</b> , 33, 1204-7		13
619	Genetics- and immune-related factors in the pathogenesis of lymphoplasmacytic lymphoma/ Waldenström's macroglobulinemia. <b>2009</b> , 9, 23-6		11
618	Assessment of bone marrow response in Waldenström's macroglobulinemia. <b>2009</b> , 9, 53-5		41
617	Soluble CD27 is a faithful marker of disease burden and is unaffected by the rituximab-induced IgM flare, as well as by plasmapheresis, in patients with Waldenström's macroglobulinemia. <b>2009</b> , 9, 56-8		16
616	Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia. <b>2009</b> , 9, 62-6		52
615	Role of proteasome inhibition in Waldenström's macroglobulinemia. <b>2009</b> , 9, 94-6		3
614	Antigenic determinants in IgM paraprotein-related neuropathies. <b>2009</b> , 9, 107-9		10
613	Cold agglutinin-mediated autoimmune hemolytic anemia in Waldenström's macroglobulinemia. <b>2009</b> , 9, 110-2		36
612	Bortezomib and Waldenstrom's macroglobulinemia. <b>2009</b> , 10, 909-16		8
611	International prognostic scoring system for Waldenstrom macroglobulinemia. <i>Blood</i> , <b>2009</b> , 113, 4163-70.2		282
610	Individualizing treatment for Waldenstrom's macroglobulinemia. <b>2009</b> , 2, 473-6		1
609	Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects. <b>2009</b> , 88, 284-293		191

608	Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. <i>Blood</i> , <b>2009</b> , 113, 3673-8	2.2	115
607	Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. <i>Blood</i> , <b>2009</b> , 113, 626-34	2.2	20
606	microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia. <i>Blood</i> , <b>2009</b> , 113, 4391-402	2.2	98
605	How I treat Waldenström macroglobulinemia. <i>Blood</i> , <b>2009</b> , 114, 2375-85	2.2	170
604	The basis and rational use of molecular genetic testing in mature B-cell lymphomas. <b>2010</b> , 17, 333-58		7
603	Plasma cell granuloma of the sigmoid colon associated with diverticular disease and accompanying IgM-type monoclonal gammopathy. <i>Internal Medicine</i> , <b>2010</b> , 49, 227-30	1.1	4
602	IgA and IgG hypogammaglobulinemia in Waldenström's macroglobulinemia. <i>Haematologica</i> , <b>2010</b> , 95, 470-5	6.6	45
601	Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. <i>Blood</i> , <b>2010</b> , 115, 4051-60	2.2	69
600	Differential characteristics of Waldenström macroglobulinemia according to patterns of familial aggregation. <i>Blood</i> , <b>2010</b> , 115, 4464-71	2.2	39
599	microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia. <i>Blood</i> , <b>2010</b> , 116, 1506-14	2.2	99
598	Heating up cold agglutinins. <i>Blood</i> , <b>2010</b> , 116, 3119-20	2.2	9
597	Paraproteinaemic Demyelinating Neuropathies. <b>2010</b> , 351-361		2
596	[Waldenstrom's macroglobulinaemia of the lacrimal gland in a patient with sarcoidosis]. <b>2010</b> , 107, 60-3		1
595	IgG-associated immune thrombocytopenia in Waldenström macroglobulinemia. <b>2010</b> , 92, 360-3		6
594	Molecular cytogenetic analysis of Korean patients with Waldenström macroglobulinemia. <b>2010</b> , 197, 117-21		12
593	Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. <b>2010</b> , 85, 670-4		104
592	Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). <b>2010</b> , 34, 1340-3		45
591	Lymphomas in the bone marrow. <b>2010</b> , 16, 125-142		2

590	European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society--first revision. <b>2010</b> , 15, 185-95	177
589	Keratotic vascular papules over the feet: a case of Waldenström's macroglobulinaemia-associated cutaneous macroglobulinosis. <b>2010</b> , 35, 278-81	7
588	Blood Disorders in the Elderly. <b>2010</b> , 775-790	
587	Maladie de Waldenström. <b>2010</b> , 16, 53-56	
586	Allogeneic stem-cell transplantation in patients with Waldenström macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <b>2010</b> , 28, 4926-34	64
585	Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. <b>2010</b> , 28, 1408-14	114
584	Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. <b>2010</b> , 28, 1422-8	118
583	Prognosis of polyneuropathy due to IgM monoclonal gammopathy: a prospective cohort study. <b>2010</b> , 74, 406-12	62
582	Orbital involvement in Bing-Neel syndrome. <b>2010</b> , 30, 255-9	17
581	High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <b>2010</b> , 28, 2227-32	106
580	Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. <b>2010</b> , 16, 1033-41	105
579	Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients. <i>Leukemia and Lymphoma</i> , <b>2010</b> , 51, 1779-92	1.9 19
578	Novel treatment regimens for Waldenström's macroglobulinemia. <b>2010</b> , 3, 339-50	13
577	Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia. <b>2010</b> , 102, 557-67	74
576	Epigenetics in Waldenström's macroglobulinemia. <b>2010</b> , 2, 691-6	2
575	Epigenetic modifications as key regulators of Waldenstrom's Macroglobulinemia biology. <b>2010</b> , 3, 38	12
574	Plasma Cell Myeloma and Other Plasma Cell Dyscrasias. <b>2010</b> , 333-348	
573	Prognosis and treatment of Waldenström's macroglobulinemia. <b>2010</b> , 42, 193-7	5

572 [Waldenström's macroglobulinemia]. **2010**, 31, 385-94

571 Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. **2010**, 85, 824-33 119

570 Emerging drugs for Waldenström's macroglobulinemia. **2011**, 16, 45-57 5

569 Classificação da Organização Mundial da Saúde para os tumores dos tecidos hematopoético e linfóide, 4ª edição, 2008 - principais modificações introduzidas em relação à 3ª edição, 2001. **2011**, 57, 66-73 3

568 World Health Organization Classification of tumors of hematopoietic and lymphoid tissues, 4th edition, 2008 [major changes from the 3rd edition, 2001]. **2011**, 57, 66-73 2

567 Successful treatment of eosinophilic colitis by montelukast sodium plus budesonide in a patient with Waldenström macroglobulinemia. **2011**, 5, 277-8 2

566 Report from the Sixth International Workshop on Waldenström's Macroglobulinemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2011**, 11, 68-73 2 11

565 What causes Waldenström's macroglobulinemia: genetic or immune-related factors, or a combination?. *Clinical Lymphoma, Myeloma and Leukemia*, **2011**, 11, 85-7 2 7

564 Associated malignancies in patients with Waldenström's macroglobulinemia and their kin. *Clinical Lymphoma, Myeloma and Leukemia*, **2011**, 11, 88-92 2 29

563 Differential diagnosis of IgM MGUS and WM according to B-lymphoid infiltration by morphology and flow cytometry. *Clinical Lymphoma, Myeloma and Leukemia*, **2011**, 11, 93-5 2 9

562 CD138 expression helps distinguishing Waldenström's macroglobulinemia (WM) from splenic marginal zone lymphoma (SMZL). *Clinical Lymphoma, Myeloma and Leukemia*, **2011**, 11, 99-102 2 14

561 Distinctive clinical and histological features of Waldenström's macroglobulinemia and splenic marginal zone lymphoma. *Clinical Lymphoma, Myeloma and Leukemia*, **2011**, 11, 103-5 2 18

560 High-throughput genomic analysis in Waldenström's macroglobulinemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2011**, 11, 106-8 2 13

559 Key role of microRNAs in Waldenström's macroglobulinemia pathogenesis. *Clinical Lymphoma, Myeloma and Leukemia*, **2011**, 11, 109-11 2 2

558 Expression of CCL3 by neoplastic cells in patients with Waldenström's macroglobulinemia: an immunohistochemical study in bone marrow biopsies of 67 patients. *Clinical Lymphoma, Myeloma and Leukemia*, **2011**, 11, 115-7 2 9

557 Pathogenesis and morbidity of autoantibody syndromes in Waldenström's macroglobulinemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2011**, 11, 157-9 2 14

556 The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. *Blood*, **2011**, 117, 5019-32 2.2 1356

555 Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenström Macroglobulinaemia who respond to a rituximab-containing regimen. *British Journal of Haematology*, **2011**, 154, 357-62 4.5 79

554	Waldenstrom macroglobulinemia with CD5+ expression presented as cryoglobulinemic glomerulonephropathy: a case report. <b>2011</b> , 26, 824-8		8
553	New insights into the pathogenesis and treatment of Waldenstrom macroglobulinemia. <b>2011</b> , 18, 260-5		13
552	Practical immunohistochemistry in hematopathology: a review of useful antibodies for diagnosis. <b>2011</b> , 18, 133-51		11
551	The neuropathies of Waldenström's macroglobulinemia (WM) and IgM-MGUS. <b>2011</b> , 38, 289-95		42
550	How I diagnose and treat splenic lymphomas. <i>Blood</i> , <b>2011</b> , 117, 2585-95	2.2	59
549	Establishment and characterization of a novel Waldenstrom macroglobulinemia cell line, MWCL-1. <i>Blood</i> , <b>2011</b> , 117, e190-7	2.2	36
548	Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab. <i>Blood</i> , <b>2011</b> , 118, 276-81	2.2	36
547	Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity. <i>Blood</i> , <b>2011</b> , 118, 5540-9	2.2	58
546	How I manage cold agglutinin disease. <i>British Journal of Haematology</i> , <b>2011</b> , 153, 309-17	4.5	61
545	Waldenström's macroglobulinemia. An overview of its clinical, biochemical, immunological and therapeutic features and our series of 121 patients collected in a single center. <b>2011</b> , 80, 87-99		10
544	Benefits and limitations of plasmapheresis in renal diseases: an evidence-based approach. <b>2011</b> , 14, 9-22		11
543	2008-WHO-Klassifikation der malignen Lymphome im Jahr 2011. <b>2011</b> , 17, 769-788		0
542	Antigenic specificity and expression of a natural idiotope on human pentameric and hexameric IgM polymers. <b>2011</b> , 51, 97-107		9
541	M protein deposition in the skin: a rare manifestation of Waldenström macroglobulinemia. <b>2011</b> , 93, 403-405		1
540	Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. <b>2011</b> , 86, 57-65		109
539	Bone marrow aspirate and trephine biopsy findings in lymphoplasmacytic lymphoma. <b>2011</b> , 86, 311-2		1
538	Waldenström macroglobulinemia: 2011 update on diagnosis, risk stratification, and management. <b>2011</b> , 86, 411-6		20
537	The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia. <b>2011</b> , 86, 567-72		29

536	Novel agents in Waldenström macroglobulinemia. <b>2011</b> , 1, 815-824	6
535	MicroRNA expression in tumor cells from Waldenstrom's macroglobulinemia reflects both their normal and malignant cell counterparts. <b>2011</b> , 1, e24	16
534	Bone-marrow plasma cell burden correlates with IgM paraprotein concentration in Waldenstrom macroglobulinaemia. <b>2011</b> , 64, 520-3	16
533	Development of diffuse large B-cell lymphoma in a patient with Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma: clonal identity between two B-cell neoplasms. <b>2011</b> , 3, e10	10
532	The bone marrow microenvironment in waldenstrom macroglobulinemia. <b>2011</b> , 2, 267-72	2
531	Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia. <b>2011</b> , 17, 1753-64	38
530	FGFR3 is overexpressed waldenstrom macroglobulinemia and its inhibition by Dovitinib induces apoptosis and overcomes stroma-induced proliferation. <b>2011</b> , 17, 4389-99	17
529	Residual monotypic plasma cells in patients with waldenstrom macroglobulinemia after therapy. <b>2011</b> , 135, 365-73	41
528	A Diagnostic Dilemma: Waldenström's Macroglobulinemia/Plasma Cell Leukemia. <b>2012</b> , 2012, 271407	1
527	Waldenström macroglobulinemia: a review of the entity and its differential diagnosis. <b>2012</b> , 19, 11-27	20
526	A multicenter phase II study of single-agent enzastaurin in previously treated Waldenstrom macroglobulinemia. <b>2012</b> , 18, 5043-50	25
525	Eph-B2/ephrin-B2 interaction plays a major role in the adhesion and proliferation of Waldenstrom's macroglobulinemia. <b>2012</b> , 18, 91-104	25
524	Hematopoietic cell transplantation for Waldenström macroglobulinemia. <b>2012</b> , 47, 330-6	16
523	Waldenström's macroglobulinemia harbors a unique proteome where Ku70 is severely underexpressed as compared with other B-lymphoproliferative disorders. <b>2012</b> , 2, e88	5
522	Genomic analysis of marginal zone and lymphoplasmacytic lymphomas identified common and disease-specific abnormalities. <b>2012</b> , 25, 651-60	54
521	Familial aggregation of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia with solid tumors and myeloid malignancies. <b>2012</b> , 127, 173-7	16
520	Risk of second cancers in Waldenström macroglobulinemia. <b>2012</b> , 23, 411-5	37
519	Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. <b>2012</b> , 10, 1211-9	31

518	IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia. <i>Blood</i> , <b>2012</b> , 120, 3774-82	2.2	33
517	The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. <i>Blood</i> , <b>2012</b> , 119, 188-91	2.2	136
516	Progression in smoldering Waldenstrom macroglobulinemia: long-term results. <i>Blood</i> , <b>2012</b> , 119, 4462-62.2		83
515	Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia. <i>Blood</i> , <b>2012</b> , 120, 3214-21	2.2	41
514	Molecular pathogenesis of Waldenstrom's macroglobulinemia. <i>Haematologica</i> , <b>2012</b> , 97, 1281-90	6.6	25
513	Cutaneous macroglobulinosis: a case series. <b>2012</b> , 39, 962-70		23
512	[Lymphomas and lymphatic leukemias in the bone marrow]. <b>2012</b> , 33, 518-27		1
511	Cast nephropathy and light-chain deposition disease in Waldenstrom macroglobulinemia. <b>2012</b> , 60, 487-91		25
510	Crioglobulinemias. <b>2012</b> , 19, 40-51		
509	Risk stratification in Waldenstrom macroglobulinemia. <b>2012</b> , 5, 187-99		12
508	Diagnosis and treatment of cold agglutinin mediated autoimmune hemolytic anemia. <b>2012</b> , 26, 107-15		108
507	A Step Forward in the Diagnosis of B-Cell Lymphomas in the Bone Marrow. <b>2012</b> , 191-221		
506	Sodium chloride vs. sodium bicarbonate for the prevention of contrast medium-induced nephropathy: a randomized controlled trial. <b>2012</b> , 33, 2071-9		70
505	Hematological Malignancies Uncommon Presentations of Plasma Cell Dyscrasias. <b>2012</b> , 627-635		
504	MYD88 L265P somatic mutation in IgM MGUS. <b>2012</b> , 367, 2255-6; author reply 2256-7		87
503	MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. <b>2012</b> , 367, 826-33		896
502	Excellent long-term survival of 170 patients with Waldenstrom's macroglobulinemia treated in private oncology practices and a university hospital. <b>2012</b> , 91, 1923-8		9
501	Bone Marrow Lymphoid Infiltrates. <b>2012</b> ,		1



500 New Insights in Waldenström Macroglobulinemia. **2012**, 223-236

499 Antibiotic use and risk of non-Hodgkin lymphomas. **2012**, 131, E1158-65

6

498 Waldenström macroglobulinemia: 2012 update on diagnosis, risk stratification, and management. **2012**, 87, 503-10

33

497 Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. **2012**, 118, 3793-800

76

496 Heterogeneous spectrum of neuropathies in Waldenström's macroglobulinemia: a diagnostic strategy to optimize their management. **2012**, 17, 90-101

36

495 Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. **2012**, 118, 434-43

77

494 Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. **2012**, 87, 78-88

106

493 Lymphoma. **2013**,

1

492 Waldenström macroglobulinaemia: the key questions. *British Journal of Haematology*, **2013**, 162, 295-303 4.5

6

491 La maladie de Waldenström ou macroglobulinémie. **2013**, 2013, 73-82

490 Actualité thérapeutiques dans les lymphomes. **2013**,

489 Genetic factors and pathogenesis of Waldenström's macroglobulinemia. **2013**, 15, 450-6

10

488 XIII. Waldenström's macroglobulinaemia: an indolent B-cell lymphoma with distinct molecular and clinical features. **2013**, 31 Suppl 1, 76-80

11

487 Neuropathy and monoclonal gammopathy. **2013**, 115, 443-59

23

486 Therapeutic effects of thalidomide in hematologic disorders: a review. **2013**, 7, 290-300

9

485 Actualité sur la maladie de Waldenström. **2013**, 34, A6-A10

484 Novel treatment options for Waldenström macroglobulinemia. *Clinical Lymphoma, Myeloma and Leukemia*, **2013**, 13 Suppl 2, S310-6

2 6

483 Associated cancers in Waldenström macroglobulinemia: clues for common genetic predisposition. *Clinical Lymphoma, Myeloma and Leukemia*, **2013**, 13, 700-3

2 14

482	Genomic studies have identified multiple mechanisms of genetic changes in Waldenström macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2013</b> , 13, 202-4	2	8
481	Paraproteinemic neuropathies. <b>2013</b> , 42, e225-34		8
480	Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). <i>Blood</i> , <b>2013</b> , 122, 3276-82	2.2	135
479	Cold agglutinin disease. <i>Blood</i> , <b>2013</b> , 122, 1114-21	2.2	168
478	Fludarabine in Waldenstrom's macroglobulinemia. <b>2013</b> , 6, 229-37		1
477	Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. <i>British Journal of Haematology</i> , <b>2013</b> , 160, 171-6	4.5	173
476	Waldenström Macroglobulinemia. <b>2013</b> , 681-699		
475	Central nervous system marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type involving the brain and spinal cord parenchyma. <b>2013</b> , 33, 306-11		12
474	Diagnosis and Treatment of Multiple Myeloma. <b>2013</b> , 637-663		2
473	Patients with Waldenström macroglobulinemia commonly present with iron deficiency and those with severely depressed transferrin saturation levels show response to parenteral iron administration. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2013</b> , 13, 241-3	2	14
472	Intraclonal heterogeneity in concomitant monoclonal lymphocyte and plasma cell populations: combining flow cytometric cell sorting with molecular monoclonality profiling. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2013</b> , 13, 214-7	2	2
471	Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrazji plazmocytoowych na rok 2013. <b>2013</b> , 44, 3-47		4
470	Immunoglobulin M concentration in Waldenström macroglobulinemia: correlation with bone marrow B cells and plasma cells. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2013</b> , 13, 211-3	2	9
469	Comparative response assessment by serum immunoglobulin M M-protein and total serum immunoglobulin M after treatment of patients with Waldenström macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2013</b> , 13, 250-2	2	7
468	Etiology of Waldenström macroglobulinemia: genetic factors and immune-related conditions. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2013</b> , 13, 194-7	2	9
467	Genomic abnormalities of Waldenström macroglobulinemia and related low-grade B-cell lymphomas. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2013</b> , 13, 198-201	2	14
466	Immunoglobulin m monoclonal gammopathy of undetermined significance and smoldering Waldenström macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2013</b> , 13, 184-6	2	9
465	Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. <b>2013</b> , 88, 226-35		92

464	Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. <i>Blood</i> , <b>2013</b> , 121, 2522-8	2.2	229
463	MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. <i>Blood</i> , <b>2013</b> , 121, 2051-8	2.2	298
462	Waldenström macroglobulinemia: my way. <i>Leukemia and Lymphoma</i> , <b>2013</b> , 54, 464-71	1.9	7
461	Clues to pathogenesis of Waldenström macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors. <i>Leukemia and Lymphoma</i> , <b>2013</b> , 54, 2485-9	1.9	20
460	MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia. <b>2013</b> , 27, 1722-8		179
459	Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management. <b>2013</b> , 88, 703-11		44
458	Lymphoplasmacytic lymphoma and Waldenström macroglobulinemia. <b>2013</b> , 137, 580-5		32
457	Development and characterization of a novel human Waldenström macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute - Waldenström Macroglobulinemia 1. <i>Leukemia and Lymphoma</i> , <b>2013</b> , 54, 387-96	1.9	20
456	Hyperviscosity in plasma cell dyscrasias. <b>2013</b> , 55, 75-83		51
455	Choice of therapy for patients with Waldenstrom macroglobulinemia. <b>2013</b> , 31, 291-3		15
454	Precursors to lymphoproliferative malignancies. <b>2013</b> , 22, 533-9		13
453	Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. <b>2013</b> , 31, 301-7		113
452	Waldenstrom's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <b>2013</b> , 24 Suppl 6, vi155-9		34
451	MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders. <b>2013</b> , 140, 387-94		45
450	Canomad: report of a case with a 40-year history and autopsy. Is this a sensory ganglionopathy with neuromuscular junction blockade?. <b>2013</b> , 48, 599-603		12
449	How to manage Waldenstrom's macroglobulinemia. <b>2013</b> , 27, 762-72		33
448	MYD88 L265P mutation in Waldenstrom macroglobulinemia. <i>Blood</i> , <b>2013</b> , 121, 4504-11	2.2	166
447	Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia. <i>Blood</i> , <b>2013</b> , 121, 1296-303	2.2	45

446	A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. <i>Blood</i> , <b>2013</b> , 122, 1222-32	2.2	252
445	Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. 190-215		
444	Diagnosis of myeloma and related plasma cell disorders. 11-27		
443	Targeting CD19 in B-cell lymphoma: emerging role of SAR3419. <b>2013</b> , 5, 225-33		19
442	Factitious Biochemical Reports which are Caused Due to Paraproteinaemia in Multiple Myeloma - A Case Report. <b>2013</b> , 7, 350-2		1
441	Waldenström's macroglobulinemia presenting with lytic bone lesions: a rare presentation. <b>2013</b> , 48, 230-3		3
440	Lymphoplasmacytic non-Hodgkin lymphoma/Waldenström's macroglobulinemia with CD5+, CD23+, and CD10-. <b>2013</b> , 48, 300-3		1
439	Candidate genes of Waldenström's macroglobulinemia: current evidence and research. <b>2013</b> , 6, 33-42		4
438	L265P mutation of the MYD88 gene is frequent in Waldenström's macroglobulinemia and its absence in myeloma. <b>2013</b> , 8, e80088		29
437	Intravitreal Injection of Dexamethasone Implant in Serous Macular Detachment Associated with Waldenström's Disease. <b>2013</b> , 4, 64-9		23
436	Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma. 138-154		
435	[Waldenström macroglobulinemia]. <b>2013</b> , 154, 1970-4		
434	CXCR4 in Central and Peripheral Lymphoid Niches [Physiology, Pathology and Therapeutic Perspectives in Immune Deficiencies and Malignancies. <b>2014</b> ,		
433	The Role of CXC-Chemokine IL-8, IL-6 and CXCR2 Receptor in Lymphoplasmacytic Lymphoma: Correlations with Microvascular Characteristics and Clinical Features. <b>2014</b> , 2, 110-118		1
432	Pathology of indolent B-cell neoplasms other than follicular lymphoma. <b>2014</b> , 54, 11-22		9
431	. <b>2014</b> ,		7
430	Current and future therapeutic approach for Waldenström's macroglobulinemia. <b>2014</b> , 6, 333-48		1
429	The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. <i>Haematologica</i> , <b>2014</b> , 99, 984-96	6.6	86

428	Predicting progression to lymphoma in Sjögren's syndrome patients. <b>2014</b> , 10, 501-12		18
427	Clonotypic analysis of immunoglobulin heavy chain sequences in patients with Waldenström's macroglobulinemia: correlation with MYD88 L265P somatic mutation status, clinical features, and outcome. <b>2014</b> , 2014, 809103		8
426	Diagnosis of splenic B-cell lymphomas in the bone marrow: a review of histopathologic, immunophenotypic, and genetic findings. <b>2014</b> , 138, 1295-301		14
425	Clinical factors associated with response or survival after chemotherapy in patients with Waldenström macroglobulinemia in Korea. <b>2014</b> , 2014, 253243		4
424	MYD88 L265P mutations are correlated with 6q deletion in Korean patients with Waldenström macroglobulinemia. <b>2014</b> , 2014, 363540		7
423	Multiparameter flow cytometry for the identification of the Waldenström's clone in IgM-MGUS and Waldenström's Macroglobulinemia: new criteria for differential diagnosis and risk stratification. <b>2014</b> , 28, 166-73		57
422	Characterization of subpopulation lacking both B-cell and plasma cell markers in Waldenstrom macroglobulinemia cell line. <b>2014</b> , 94, 79-88		5
421	Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. <b>2014</b> , 89, 237-42		60
420	Transcriptional repression of plasma cell differentiation is orchestrated by aberrant over-expression of the ETS factor SPIB in Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , <b>2014</b> , 166, 677-89	4.5	14
419	Rare Lymphomas. <b>2014</b> ,		
418	Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction. <b>2014</b> , 22, 768-73		22
417	MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome. <i>British Journal of Haematology</i> , <b>2014</b> , 167, 506-13	4.5	49
416	IgM monoclonal gammopathy in gastric MALToma. <b>2014</b> , 45, 91-5		0
415	The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. <i>Blood</i> , <b>2014</b> , 123, 1637-46	2.2	308
414	Waldenström macroglobulinemia: from biology to treatment. <b>2014</b> , 7, 157-68		14
413	Detection of MYD88 L265P in peripheral blood of patients with Waldenström's Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. <b>2014</b> , 28, 1698-704		73
412	Nimbolide targets BCL2 and induces apoptosis in preclinical models of Waldenström's macroglobulinemia. <b>2014</b> , 4, e260		17
411	Community-acquired infections associated with increased risk of lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , <b>2014</b> , 164, 653-8	4.5	7

410	Guidelines on the diagnosis and management of Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , <b>2014</b> , 165, 316-33	4.5	46
409	Incidence of lymphoplasmacytic lymphoma/Waldenström's macroglobulinaemia in Japan and Taiwan population-based cancer registries, 1996-2003. <b>2014</b> , 134, 174-80		20
408	Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management. <b>2014</b> , 89, 999-1009		123
407	Neoplasms of Mature B, T and NK Cells. <b>2014</b> , 587-680		
406	Waldenström macroglobulinemia. <b>2014</b> , 28, 945-70		19
405	Detection of MYD88 L265P mutations in formalin-fixed and decalcified BM biopsies from patients with lymphoplasmacytic lymphoma. <b>2014</b> , 97, 57-65		8
404	Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. <i>Blood</i> , <b>2014</b> , 123, 2791-6	2.2	260
403	Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. <i>Blood</i> , <b>2014</b> , 124, 1404-11	2.2	107
402	Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. <i>Blood</i> , <b>2014</b> , 124, 503-10	2.2	127
401	Waldenström macroglobulinemia at 70. <b>2014</b> , 3, 253-266		
400	Bing-Neel syndrome, a rare complication of Waldenström macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO). <i>Haematologica</i> , <b>2015</b> , 100, 1587-94	6.6	75
399	Intravitreal bevacizumab: a viable treatment for bilateral central retinal vein occlusion with serous macular detachment secondary to Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , <b>2015</b> , 170, 431-4	4.5	9
398	The cellular origin and malignant transformation of Waldenström macroglobulinemia. <i>Blood</i> , <b>2015</b> , 125, 2370-80	2.2	51
397	Macro-quest. <i>Blood</i> , <b>2015</b> , 125, 2318-9	2.2	2
396	Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study. <i>Blood</i> , <b>2015</b> , 126, 1392-4	2.2	67
395	Preclinical activity of the repurposed drug auranofin in classical Hodgkin lymphoma. <i>Blood</i> , <b>2015</b> , 126, 1394-7	2.2	40
394	CD4+CD25+ cells in multiple myeloma related renal impairment. <b>2015</b> , 5, 16565		5
393	Lenalidomide is safe and active in Waldenström macroglobulinemia. <b>2015</b> , 90, 1055-9		16

392	MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity. <i>British Journal of Haematology</i> , <b>2015</b> , 169, 795-803	4.5	65
391	Cutaneous crystal storing histiocytosis: a report of two cases. <b>2015</b> , 42, 136-43		11
390	Characteristic OCT Pattern in Waldenstrom Macroglobulinemia. <b>2015</b> , 92, e106-9		7
389	Immunophenotyping of Waldenström's macroglobulinemia cell lines reveals distinct patterns of surface antigen expression: potential biological and therapeutic implications. <b>2015</b> , 10, e0122338		9
388	How I treat Waldenström macroglobulinemia. <i>Blood</i> , <b>2015</b> , 126, 721-32	2.2	105
387	Waldenström macroglobulinemia: 2015 update on diagnosis, risk stratification, and management. <b>2015</b> , 90, 346-54		33
386	Waldenström macroglobulinemia: What a hematologist needs to know. <b>2015</b> , 29, 301-19		29
385	Kidney diseases associated with monoclonal immunoglobulin M-secreting B-cell lymphoproliferative disorders: a case series of 35 patients. <b>2015</b> , 66, 756-67		47
384	Bilateral Choroidal Detachment in Waldenström Macroglobulinemia. <b>2015</b> , 133, 715-6		1
383	Hypoxia promotes dissemination and colonization in new bone marrow niches in Waldenström macroglobulinemia. <b>2015</b> , 13, 263-72		21
382	Extramedullary Waldenström macroglobulinemia. <b>2015</b> , 90, 100-4		31
381	Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease. <b>2015</b> , 88, 1135-43		82
380	Ibrutinib for the treatment of Waldenström macroglobulinemia. <b>2015</b> , 8, 569-79		12
379	Tropical Hemato-Oncology. <b>2015</b> ,		2
378	Successful treatment of refractory cold hemagglutininemia in MYD88 L265P mutation-negative Waldenström's macroglobulinemia with bortezomib. <b>2015</b> , 102, 238-43		2
377	Lymphoplasmacytic lymphoma and marginal zone lymphoma in the bone marrow: paratrabecular involvement as an important distinguishing feature. <b>2015</b> , 143, 797-806		22
376	Pathology of B-cell lymphomas: diagnosis and biomarker discovery. <b>2015</b> , 165, 27-50		8
375	Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrazji plazmocytoowych na rok 2015. <b>2015</b> , 46, 159-211		



374	Ibrutinib in previously treated Waldenström's macroglobulinemia. <b>2015</b> , 372, 1430-40		617
373	Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. <b>2015</b> , 15, 1143-56		5
372	Bone marrow assessment in asymptomatic immunoglobulin M monoclonal gammopathies. <i>British Journal of Haematology</i> , <b>2015</b> , 168, 301-2	4.5	5
371	Bone marrow assessment in asymptomatic IgM monoclonal gammopathies - reply to Varettoni et al. <i>British Journal of Haematology</i> , <b>2015</b> , 168, 302-3	4.5	1
370	Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells. <i>British Journal of Haematology</i> , <b>2015</b> , 169, 377-90	4.5	47
369	Sarcoidosis presenting as late-onset dementia: are cerebrospinal fluid biomarkers analyses helpful?. <b>2015</b> , 63, 198-200		1
368	Persistent dizziness. <b>2015</b> , 63, 197-8		
367	Phase II clinical trials for Waldenström macroglobulinemia. <b>2015</b> , 3, 537-547		
366	Phase I/II trial of everolimus in combination with bortezomib and rituximab (RVR) in relapsed/refractory Waldenström macroglobulinemia. <b>2015</b> , 29, 2338-46		27
365	Paraproteinemic neuropathies. <b>2015</b> , 51, 1-13		29
364	12. Waldenström macroglobulinemia. <b>2016</b> , 229-244		
363	Waldenström macroglobulinemia: biology, genetics, and therapy. <b>2016</b> , 6, 49-58		3
362	Bing-Neel Syndrome: Illustrative Cases and Comprehensive Review of the Literature. <b>2017</b> , 9, e2017061		10
361	Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. <i>British Journal of Haematology</i> , <b>2016</b> , 172, 709-15	4.5	60
360	Donor Monoclonal Gammopathy May Cause Lymphoproliferative Disorders in Solid Organ Transplant Recipients. <b>2016</b> , 16, 2676-83		4
359	Familial Waldenström's macroglobulinemia and relation to immune defects, autoimmune diseases, and haematological malignancies--A population-based study from northern Sweden. <b>2016</b> , 55, 91-8		8
358	The clinical spectrum of IgM monoclonal gammopathy: A single center retrospective study of 377 patients. <b>2016</b> , 46, 85-8		17
357	Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenström Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2016</b> , 16, 395-403.e1	2	13



356	Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia. <i>Blood</i> , <b>2016</b> , 128, 827-38	2.2	63
355	Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. <i>Blood</i> , <b>2016</b> , 128, 1321-8	2.2	125
354	Current therapy guidelines for Waldenstrom's macroglobulinaemia. <b>2016</b> , 29, 194-205		4
353	Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia. <b>2016</b> , 29, 187-193		4
352	Plasma Cell Dyscrasias. <b>2016</b> ,		1
351	Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment. <b>2016</b> , 169, 321-361		3
350	Prognostic factors and indications for treatment of Waldenström's Macroglobulinemia. <b>2016</b> , 29, 179-186		7
349	Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis. <b>2016</b> , 21, 1377-1386		28
348	Histological transformation to diffuse large B-cell lymphoma in patients with Waldenström macroglobulinemia. <b>2016</b> , 91, 1032-5		34
347	Rituximab intolerance in patients with Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , <b>2016</b> , 174, 645-8	4.5	29
346	Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes. <i>British Journal of Haematology</i> , <b>2016</b> , 175, 623-630	4.5	51
345	Recommendations for the diagnosis and initial evaluation of patients with Waldenström Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenström Macroglobulinaemia. <i>British Journal of Haematology</i> , <b>2016</b> , 175, 77-86	4.5	41
344	The role of stem cell transplantation in Waldenstrom's macroglobulinemia. <b>2016</b> , 29, 229-240		3
343	Plasma Cell Disorders. <b>2016</b> , 43, 677-691		11
342	Efficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom's macroglobulinemia. <b>2016</b> , 91, 782-6		20
341	Immunoglobulin M 'Flare' Seen in a Case of Waldenstrom's Macroglobulinemia: Successfully Managed by Therapeutic Plasma Exchange. <b>2016</b> , 32, 148-51		1
340	Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrazji plazmocytoowych na rok 2016. <b>2016</b> , 47, 39-85		8
339	Simultaneous occurrence of fibrillary glomerulonephritis and renal lesions in nonmalignant monoclonal IgM gammopathy. <b>2016</b> , 17, 17		2

338	Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia. <i>British Journal of Haematology</i> , <b>2016</b> , 172, 735-44	4.5	88
337	Requirement of CXCL12-CXCR7 signaling for CD20(-) CD138(-) double-negative population in lymphoplasmacytic lymphoma. <b>2016</b> , 96, 517-25		4
336	Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection. <b>2016</b> , 17, 16		10
335	TCL1 expression patterns in Waldenström macroglobulinemia. <b>2016</b> , 29, 83-8		4
334	Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 1104-13	1.9	27
333	Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management. <b>2017</b> , 92, 209-217		37
332	Welcome to the 9th Volume of Immunotherapy. <b>2017</b> , 9, 1-3		1
331	Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel. <i>British Journal of Haematology</i> , <b>2017</b> , 176, 728-742	4.5	34
330	Monoclonal gammopathy of renal significance (MGRS): the characteristics and significance of a new meta-entity. <b>2017</b> , 49, 2171-2175		20
329	Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , <b>2017</b> , 177, 717-725	4.5	44
328	Role of plasma cells in Waldenström macroglobulinaemia. <b>2017</b> , 49, 337-345		8
327	Management of Lymphomas: A Case-Based Approach. <b>2017</b> ,		
326	Effect of plasma-activated medium on the decrease of tumorigenic population in lymphoma. <b>2017</b> , 213, 773-777		7
325	Waldenstrom macroglobulinemia cells devoid of BTK or CXCR4 mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. <b>2017</b> , 7, e565		32
324	[Bilateral infiltrative optic neuropathy as presenting sign of Waldenström macroglobulinemia]. <b>2017</b> , 40, e95-e96		
323	Immunoparesis in IgM gammopathies as a useful biomarker to predict disease progression. <b>2017</b> , 55, 1598-1604		6
322	Uncommon Presentations of Plasma Cell Dyscrasias. <b>2017</b> , 776-792		2
321	Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease. <b>2017</b> , 96, 971-976		14

320	Waldenström Macroglobulinemia: Review of Pathogenesis and Management. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2017</b> , 17, 252-262	2	25
319	Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iINNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. <b>2017</b> , 18, 241-250		159
318	Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. <i>Haematologica</i> , <b>2017</b> , 102, 43-51	6.6	72
317	Current applications of multiparameter flow cytometry in plasma cell disorders. <b>2017</b> , 7, e617		26
316	Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. <i>Haematologica</i> , <b>2017</b> , 102, 2077-2085	6.6	43
315	From Waldenström's macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation. <b>2017</b> , 7, e591		14
314	Rare transformation to double hit lymphoma in Waldenstrom's macroglobulinemia. <b>2017</b> , 9, 709-714		0
313	Imbruvica?(ibrutinib) patient support programme for chronic lymphocytic leukaemia and mantle cell lymphoma. <b>2017</b> , 26, S20-S25		1
312	Zalecenia Polskiej Grupy Szpiczakowej dotyczące rozpoznawania i leczenia szpiczaka plazmocytoowego oraz innych dyskrazji plazmocytoowych na rok 2017. <b>2017</b> , 48, 55-103		3
311	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia. <i>British Journal of Haematology</i> , <b>2017</b> , 179, 98-105	4.5	12
310	Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO). <i>British Journal of Haematology</i> , <b>2017</b> , 179, 439-448	4.5	24
309	[Waldenström's macroglobulinemia and its individualized therapy options]. <b>2017</b> , 158, 1604-1614		1
308	Retrospective analysis of prognostic factors for Waldenström macroglobulinemia: a multicenter cooperative study in Japan. <b>2017</b> , 106, 681-690		2
307	Percorso di laboratorio raccomandato nella diagnosi, prognosi e follow-up delle gammopatie monoclonali. <b>2017</b> , 13, 10-23		1
306	Phase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström's macroglobulinemia. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 1506-1508	1.9	8
305	To select or not to select? The role of B-cell selection in determining the MYD88 mutation status in Waldenström Macroglobulinaemia. <i>British Journal of Haematology</i> , <b>2017</b> , 176, 822-824	4.5	19
304	Idelalisib in Waldenström macroglobulinemia: high incidence of hepatotoxicity. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 1002-1004	1.9	27
303	Waldenström's Macroglobulinemia. <b>2017</b> ,		

302	Waldenström Macroglobulinaemia: Pathological Features and Diagnostic Assessment. <b>2017</b> , 3-19		
301	Immunoglobulin Type M Monoclonal Gammopathy of Undetermined Significance (IgM-MGUS). <b>2017</b> , 143-167		
300	Neuropathy in Waldenström Macroglobulinaemia. <b>2017</b> , 185-194		
299	Laboratory Investigations and Findings: Hematological Abnormalities, Biochemical Investigations, Free Light and Heavy Chains. <b>2017</b> , 239-261		
298	Response Assessment in Waldenström Macroglobulinaemia. <b>2017</b> , 265-275		
297	Waldenström Macroglobulinemia Immunophenotype. <b>2017</b> , 21-34		0
296	Indications for Treatment of Waldenström Macroglobulinemia. <b>2017</b> , 297-313		
295	Genetic and Signaling Abnormalities in Waldenstrom Macroglobulinemia. <b>2017</b> , 53-65		1
294	Waldenstrom Macroglobulinaemia: Immunosurveillance and the Immune Micro-environment. <b>2017</b> , 83-94		
293	Biology and Management of Unusual Plasma Cell Dyscrasias. <b>2017</b> ,		
292	Waldenstrom Macroglobulinemia. <b>2017</b> , 71-93		
291	Toward personalized treatment in Waldenström macroglobulinemia. <b>2017</b> , 2017, 365-370		5
290	Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia. <b>2017</b> , 35, 994-1001		47
289	Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia. <i>British Journal of Haematology</i> , <b>2018</b> , 181, 77-85	4.5	28
288	True, true unrelated? Coexistence of Waldenström macroglobulinemia and cardiac transthyretin amyloidosis. <i>Haematologica</i> , <b>2018</b> , 103, e374-e376	6.6	4
287	Fifty-Year Incidence of Waldenström Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review. <b>2018</b> , 93, 739-746		16
286	Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenström Macroglobulinemia. <b>2018</b> , 24, 3247-3252		42
285	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. <b>2018</b> , 97, 1417-1425		43

284	Waldenström Macroglobulinemia. <b>2018</b> , 191-220		1
283	Unraveling the heterogeneity of IgM monoclonal gammopathies: a gene mutational and gene expression study. <b>2018</b> , 97, 475-484		6
282	Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound. <b>2018</b> , 93, 511-517		41
281	Primary hepatic marginal zone lymphoma: A rare coincidence. <b>2018</b> , 42, 322-328		4
280	Waldenström macroglobulinemia treatment algorithm 2018. <b>2018</b> , 8, 40		10
279	Ibrutinib withdrawal symptoms in patients with Waldenström macroglobulinemia. <i>Haematologica</i> , <b>2018</b> , 103, e307-e310	6.6	30
278	mutated and wild-type Waldenström's Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in. <i>Haematologica</i> , <b>2018</b> , 103, e408-e411	6.6	14
277	Efficacy of ibrutinib as first-line treatment of tumoral Bing-Neel syndrome. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 2746-2748	1.9	10
276	Diagnosis and management of neuropathies associated with plasma cell dyscrasias. <b>2018</b> , 36, 3-14		11
275	High prevalence of the mutation in IgM anti-MAG paraprotein-associated peripheral neuropathy. <b>2018</b> , 89, 1007-1009		10
274	Neurologic Complications of Plasma Cell Dyscrasias. <b>2018</b> , 583-595		1
273	A rare neurological complication of Waldenstrom's Macroglobulinemia. <b>2018</b> , 48, 143-146		5
272	MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival. <i>British Journal of Haematology</i> , <b>2018</b> , 180, 374-380	4.5	51
271	Clinical Presentation and Gene Expression Profiling of Immunoglobulin M Multiple Myeloma Compared With Other Myeloma Subtypes and Waldenström Macroglobulinemia. <b>2018</b> , 4, 1-8		1
270	Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia. <b>2018</b> , 36, 2755-2761		91
269	Multiple cystic lung lesions and autoimmune thrombocytopaenia developing after chemotherapy for pulmonary indolent B-cell lymphoma with plasmacytic differentiation. <b>2018</b> , 11,		
268	Waldenstrom's Macroglobulinemia: An Update. <b>2018</b> , 10, e2018004		15
267	Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenström Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent. <b>2018</b> , 53, 117-122		3

266	Paraproteinaemia in Primary Cutaneous Marginal Zone Lymphoma. <b>2018</b> , 98, 956-962		4
265	A Case of Bing-Neel Syndrome Successfully Treated with Ibrutinib. <b>2018</b> , 2018, 8573105		4
264	Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <b>2018</b> , 29, iv41-iv50		28
263	Effect of glutamine on lymphoplasmacytic lymphoma, especially on the viewpoint of the differentiation into vulnerable subpopulation. <b>2018</b> , 214, 1667-1674		
262	Prognostic factors and primary treatment for Waldenström macroglobulinemia - a Swedish Lymphoma Registry study. <i>British Journal of Haematology</i> , <b>2018</b> , 183, 564-577	4-5	4
261	Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia. <i>Blood Advances</i> , <b>2018</b> , 2, 3102-3111	7-8	0
260	Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia. <b>2018</b> , 378, 2399-2410		189
259	Defining Lymphoplasmacytic Lymphoma: Does MYD88L265P Define a Pathologically Distinct Entity Among Patients With an IgM Paraprotein and Bone Marrow-Based Low-Grade B-Cell Lymphomas With Plasmacytic Differentiation?. <b>2018</b> , 150, 168-176		4
258	Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review. <b>2018</b> , 5, e299-e309		24
257	Proteasome Inhibitors in Waldenström Macroglobulinemia. <b>2018</b> , 32, 829-840		3
256	European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. <b>2018</b> , 32, 1883-1898		58
255	The Pathologic Basis for the Classification of Non-Hodgkin and Hodgkin Lymphomas. <b>2018</b> , 1187-1203		0
254	Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma. <b>2018</b> , 1419-1431.e5		
253	Flow Cytometry. <b>2018</b> , 32, 765-775		6
252	Waldenström Macroglobulinemia. <b>2018</b> , 617-638		
251	Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol. <b>2018</b> , 18, 187		9
250	Pulmonary extranodal marginal zone lymphoma that presented with macroglobulinemia and marked plasmacytic cell proliferation carrying the t(14;18)(q32;q21)/MALT1-immunoglobulin heavy-chain fusion gene in pleural fluid. <b>2018</b> , 58, 141-147		3
249	Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders. <b>2018</b> , 13, 1037-1046		32

248 B-Cell Lymphocytosis. **2018**, 329-381

247 Monoclonal Gammopathies. **2019**, 1079-1093.e1

246 Update on Lymphoma classification: The 2016 revised World Health Organization Classification of Hematopoietic and Lymphoid Neoplasms. **2019**, 2, e57 1

245 Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network. **2019**, 94, 1193-1199 9

244 How we manage Bing-Neel syndrome. *British Journal of Haematology*, **2019**, 187, 277-285 4.5 17

243 Asymptomatic Waldenström Macroglobulinemia: Should We Consider a Different Terminology?. **2019**, 37, 2700-2701 2

242 The MYD88 conundrum in IgM monoclonal gammopathy of undetermined significance. *British Journal of Haematology*, **2019**, 187, 413-415 4.5 2

241 Characteristics of Waldenström Macroglobulinemia in Korean Patients According to Mutational Status of MYD88 and CXCR4: Analysis Using Ultra-Deep Sequencing. *Clinical Lymphoma, Myeloma and Leukemia*, **2019**, 19, e496-e505 2 3

240 A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders. *British Journal of Haematology*, **2019**, 187, 441-446 4.5 5

239 CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib. *British Journal of Haematology*, **2019**, 187, 356-363 4.5 41

238 Imaging of Waldenström Macroglobulinemia: A Comprehensive Review for the Radiologist in the Era of Personalized Medicine. **2019**, 213, W248-W256 3

237 Simultaneous Presentation of Waldenström's Macroglobulinemia and MYD88 Gene Mutation with Multiple Myeloma. **2019**, 11, e3822

236 Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma. **2019**, 33, 639-656 5

235 Evaluating ibrutinib in the treatment of symptomatic Waldenström's macroglobulinemia. **2019**, 10, 291-300 11

234 WITHDRAWN: Updates in Prognostication and Treatment of Waldenström Macroglobulinemia. **2019**, 1

233 Detection of MYD88 L265P mutation by next-generation deep sequencing in peripheral blood mononuclear cells of Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. **2019**, 14, e0221941 6

232 How I treat Waldenström macroglobulinemia. *Blood*, **2019**, 134, 2022-2035 2.2 23

231 Quadralvalvular Noninfectious Endocarditis. **2019**, 1, 350-354 1



230 Reply to F.D. Leonard. **2019**, 37, 2701-2702

229	Cryoglobulinemia as a Possible Primer for TRALI: Report of a Case. <b>2019</b> , 50, 313-319		1
228	Vasoproliferative retinopathy secondary to Waldenström's disease. <b>2019</b> , 94, 85-89		3
227	MALT lymphoma with IgM paraprotein and bone marrow involvement mimicking Waldenström macroglobulinaemia. <b>2019</b> , 51, 549-553		
226	Malabsorption and Malnutrition Disorders. <b>2019</b> , 191-238		1
225	Updates in prognostication and treatment of Waldenström's macroglobulinemia. <b>2019</b> , 12, 179-188		4
224	MYD88L265P mutated IgA lymphoplasmacytic lymphoma. <b>2019</b> , 75, 608-612		
223	A revised international prognostic score system for Waldenström's macroglobulinemia. <b>2019</b> , 33, 2654-2661		27
222	Rituximab-based combination therapy in patients with Waldenström macroglobulinemia: a systematic review and meta-analysis. <b>2019</b> , 12, 2751-2766		5
221	A 50-Year-Long Study of Waldenström Macroglobulinemia. <b>2019</b> , 94, 394-396		1
220	Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. <b>2019</b> , 37, 1403-1411		36
219	The role of high serum CXCL13 level in Waldenström macroglobulinemia. <b>2019</b> , 81, 50-55		
218	A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation. <b>2019</b> , 9, 796-811		11
217	Vasoproliferative retinopathy secondary to Waldenström's disease. <b>2019</b> , 94, 85-89		
216	Rare case of Bing-Neel syndrome treated successfully with ibrutinib. <b>2019</b> , 12,		1
215	clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia. <i>Blood Advances</i> , <b>2019</b> , 3, 2800-2803	7.8	19
214	Successful treatment of non-IgM lymphoplasmacytic lymphoma by bortezomib-containing regimen: case reports and review of literature. <b>2019</b> , 54, 236-240		2
213	Elevated vWF Antigen Serum Levels Are Associated With Poor Prognosis, and Decreased Circulating ADAMTS-13 Antigen Levels Are Associated With Increased IgM Levels and Features of WM but not Increased vWF Levels in Patients With Symptomatic WM. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2019</b> , 19, 23-28	2	0



212	Diagnostic framing of IgM monoclonal gammopathy: Focus on Waldenström macroglobulinemia. <b>2019</b> , 37, 117-128		7
211	Randall-type monoclonal immunoglobulin deposition disease: novel insights from a nationwide cohort study. <i>Blood</i> , <b>2019</b> , 133, 576-587	2.2	40
210	Long survival in patients with Waldenström macroglobulinaemia diagnosed at a young age. <i>British Journal of Haematology</i> , <b>2019</b> , 185, 799-802	4.5	3
209	Kidney diseases associated with Waldenström macroglobulinemia. <b>2019</b> , 34, 1644-1652		6
208	Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management. <b>2019</b> , 94, 266-276		43
207	Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. <i>Blood</i> , <b>2019</b> , 133, 299-305	2.2	41
206	Chimeric antigen receptor T cells for treatment of transformed Waldenström macroglobulinemia. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 465-468	1.9	6
205	IgM paraprotein-associated peripheral neuropathy: small CD20-positive B-cell clones may predict a monoclonal gammopathy of neurological significance and rituximab responsiveness. <i>British Journal of Haematology</i> , <b>2020</b> , 188, 511-515	4.5	3
204	Multiple Myeloma and Related Disorders. <b>2020</b> , 1884-1910.e7		2
203	Bing-Neel syndrome presenting as isolated CNS lymphoplasmacytic lymphoma: A case report and review of the literature. <b>2020</b> , 71, 277-280		2
202	Deepening of response after completing rituximab-containing therapy in patients with Waldenström macroglobulinemia. <b>2020</b> , 95, 372-378		2
201	Health-related quality of life in Waldenström Macroglobulinemia and IgM-related disorders: A single institution experience. <b>2020</b> , 38, 111-113		1
200	Validation and further potentialities of the novel AWM score for progression risk stratification in patients with asymptomatic Waldenström macroglobulinemia. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 987-989 <sup>1,9</sup>		
199	A Puzzling Case of Hyperviscosity Syndrome. <b>2020</b> , 5, 209-213		
198	Management of intraoral bleeding in patients with Waldenström macroglobulinemia: A protocol proposal. <b>2020</b> , 40, 134-141		
197	A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group. <b>2020</b> , 52, 167-178		6
196	Trends in Incidence and Mortality of Waldenström Macroglobulinemia: A Population-Based Study. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 1712	5.3	4
195	Response and Survival Outcomes to Ibrutinib Monotherapy for Patients With Waldenström Macroglobulinemia on and off Clinical Trials. <b>2020</b> , 4, e363		5

194	Management of Waldenström macroglobulinemia in 2020. <b>2020</b> , 2020, 372-379		10
193	Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. <i>Blood</i> , <b>2020</b> , 136, 2027-2037	2.2	33
192	A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia. <i>Cancer Science</i> , <b>2020</b> , 111, 3327-3337	6.9	30
191	Efficacy of Autologous and Allogeneic Hematopoietic Cell Transplantation in Waldenström Macroglobulinemia: A Systematic Review and Meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2020</b> , 20, e694-e711	2	6
190	Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies. <b>2020</b> , 95, 1473-1478		2
189	Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up. <i>Blood Advances</i> , <b>2020</b> , 4, 3952-3959	7.8	16
188	Emerging drugs for the treatment of Waldenström macroglobulinemia. <b>2020</b> , 25, 433-444		1
187	B-Cell-Specific Myd88 L252P Expression Causes a Premalignant Gammopathy Resembling IgM MGUS. <b>2020</b> , 11, 602868		2
186	Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. <i>Blood Advances</i> , <b>2020</b> , 4, 6009-6018	7.8	20
185	Outcome of stem cell transplantation for Waldenström's macroglobulinemia: analysis of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) Lymphoma Working Group. <b>2020</b> , 99, 1635-1642		0
184	Identification of 2 DNA methylation subtypes of Waldenström macroglobulinemia with plasma and memory B-cell features. <i>Blood</i> , <b>2020</b> , 136, 585-595	2.2	5
183	Diagnosis of a difficult to differentiate case of early-onset hyperviscosity syndrome caused by IgM type multiple myeloma: a case report. <b>2020</b> , 112, 741-745		1
182	Novel tumor-targeted liposomes comprised of an MDM2 antagonist plus proteasome inhibitor display anti-tumor activity in a xenograft model of bortezomib-resistant Waldenstrom macroglobulinemia. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 2399-2408	1.9	2
181	Brain Injury and Neurologic Outcome in Patients Undergoing Extracorporeal Cardiopulmonary Resuscitation: A Systematic Review and Meta-Analysis. <b>2020</b> , 48, e611-e619		13
180	Detection of the MYD88 and CXCR4 mutations by cell-free DNA in Waldenström macroglobulinemia. <b>2020</b> , 99, 1763-1769		5
179	TLR-mediated activation of Waldenström macroglobulinemia B cells reveals an uncoupling from plasma cell differentiation. <i>Blood Advances</i> , <b>2020</b> , 4, 2821-2836	7.8	3
178	The current role of BTK inhibitors in the treatment of Waldenstrom's Macroglobulinemia. <b>2020</b> , 20, 663-674		4
177	Incidence, prevalence, mortality, and causes of death in Waldenström macroglobulinemia: a nationwide, population-based cohort study. <b>2020</b> , 20, 623		2

176	Diagnostic value of bone marrow core biopsy patterns in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia and description of its mutational profiles by targeted NGS. <b>2020</b> , 73, 571-577		1
175	Cause-specific mortality in individuals with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia, 2000-2016. <i>British Journal of Haematology</i> , <b>2020</b> , 189, 1107-1118	4.5	2
174	Waldenstrom's macroglobulinemia in the era of immunotherapy. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 1292-1304	1.9	1
173	The Non-Coding RNA Landscape of Plasma Cell Dyscrasias. <b>2020</b> , 12,		14
172	6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival. <i>British Journal of Haematology</i> , <b>2021</b> , 192, 843-852	4.5	7
171	Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib. <i>British Journal of Haematology</i> , <b>2021</b> , 192, 542-550	4.5	3
170	CXCR4 in Waldenström's Macroglobulinemia: chances and challenges. <b>2021</b> , 35, 333-345		15
169	Case 6-2021: A 65-Year-Old Man with Eye Pain and Decreased Vision. <b>2021</b> , 384, 745-753		0
168	Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. <b>2021</b> , 39, 565-575		40
167	Approach to the patient with CNS lymphoma. <b>2021</b> , 172-185		1
166	Current and novel BTK inhibitors in Waldenström's macroglobulinemia. <b>2021</b> , 12, 2040620721989586		4
165	An unusual case of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia presenting with intractable seizures and interference with automated testing. <b>2021</b> , 14, 69-73		1
164	Flow cytometry detection of CD138 expression continuum between monotypic B and plasma cells is associated with both high IgM peak levels and MYD88 mutation and contributes to diagnosis of Waldenström macroglobulinemia. <b>2021</b> ,		1
163	Screening and identification of a novel FHL2 mutation by whole exome sequencing in twins with familial Waldenström macroglobulinemia. <b>2021</b> , 127, 2039-2048		0
162	Time to Move to the Single-Cell Level: Applications of Single-Cell Multi-Omics to Hematological Malignancies and Waldenström's Macroglobulinemia-A Particularly Heterogeneous Lymphoma. <b>2021</b> , 13,		3
161	Defining an Ultra-Low Risk Group in Asymptomatic IgM Monoclonal Gammopathy. <b>2021</b> , 13,		1
160	MYD88 Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation. <i>Diagnostics</i> , <b>2021</b> , 11,	3.8	3
159	Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia. <b>2021</b> , 23, 361-374		4

158	Identification of a Candidate Gene Set Signature for the Risk of Progression in IgM MGUS to Smoldering/Symptomatic Waldenström Macroglobulinemia (WM) by a Comparative Transcriptome Analysis of B Cells and Plasma Cells. <b>2021</b> , 13,		1
157	Transformation of IgM-MGUS into Waldenström's macroglobulinemia in two of six patients treated for Schnitzler's syndrome. <b>2021</b> , 67, e15-e23		0
156	Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia. <i>Blood Advances</i> , <b>2021</b> , 5, 2438-2446	7.8	5
155	Waldenstrom's macroglobulinemia with peripheral neuropathy and favorable long-term treatment responses. <b>2021</b> , 2, e0111		
154	Waldenström macroglobulinemia and relationship to immune deficiency. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 2665-2670	1.9	0
153	A Case of Bing-Neel Syndrome Treated Successfully With Ibrutinib Monotherapy Following Intensive Chemoimmunotherapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2021</b> , 21, e817-e819	2	0
152	Treatment and outcome patterns of patients with Waldenström's macroglobulinemia: a large, multicenter retrospective review in China. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 2657-2664	1.9	0
151	Managing complications secondary to Waldenström's macroglobulinemia. <b>2021</b> , 14, 621-632		
150	Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy. <i>Haematologica</i> , <b>2021</b> ,	6.6	2
149	The Spectrum of Ocular Manifestations in Patients with Waldenström's Macroglobulinemia. <b>2021</b> , 1-10		2
148	Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia. <i>Blood</i> , <b>2021</b> , 138, 1535-1539	2.2	7
147	Waldenström's Macroglobulinemia: An Exploration into the Pathology and Diagnosis of a Complex B-Cell Malignancy. <b>2021</b> , 12, 795-807		1
146	Ibrutinib plus rituximab for the treatment of adult patients with Waldenström's macroglobulinemia: a safety evaluation. <b>2021</b> , 20, 987-995		1
145	Primary mucosa-associated lymphoid tissue lymphoma in the midbrain: A case report. <b>2021</b> , 9, 6566-6574		0
144	Multimodal imaging of bilateral immunogammopathy maculopathy associated to Waldenström's macroglobulinemia. <b>2021</b> , 11206721211039342		
143	Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia: A review. <b>2021</b> , 10781552211038309		2
142	Watch and wait in Waldenström macroglobulinaemia: looking for who to watch carefully and who can wait without worrying. Is it that simple?. <i>British Journal of Haematology</i> , <b>2021</b> , 195, 155-157	4.5	0
141	Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. <b>2021</b> ,		10

140	Analysis of the MYD88 L265P mutation in IgM monoclonal gammopathy by semi-nested polymerase chain reaction-based restriction fragment length polymorphism method. <b>2021</b> , 33, 47-54		
139	Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management. <b>2021</b> , 96, 258-269		12
138	The indolent B-cell lymphomas. <b>2006</b> , 131, 89-120		2
137	Paraneoplastic Neuromuscular Disorders. <b>2014</b> , 1501-1514		1
136	Mature B-Cell Neoplasms. <b>2011</b> , 221-246		4
135	Lymphoplasmacytic Lymphoma/Waldenström's Macroglobulinemia. <b>2006</b> , 374-380		2
134	World Health Organization Classification of tumors of hematopoietic and lymphoid tissues, 4th edition, 2008 [major changes from the 3rd edition, 2001]. <b>2011</b> , 57, 66-73		5
133	Are you sure this is Waldenström macroglobulinemia?. <b>2012</b> , 2012, 586-594		27
132	Advances in the understanding of IgM monoclonal gammopathy of undetermined significance. <b>2017</b> , 6, 2142		3
131	Inherited polymorphisms in hyaluronan synthase 1 predict risk of systemic B-cell malignancies but not of breast cancer. <b>2014</b> , 9, e100691		6
130	The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions. <b>2017</b> , 8, 35435-35444		3
129	How I treat rituximab refractory patients with WM. <b>2018</b> , 9, 36824-36825		6
128	Lymphoplasmacytic Lymphoma Presenting with Diarrhea and Joint Pain Which was Successfully Diagnosed by an MYD88 Mutation Analysis. <i>Internal Medicine</i> , <b>2017</b> , 56, 847-851	1.1	3
127	A prognostic index predicting survival in transformed Waldenström macroglobulinemia. <i>Haematologica</i> , <b>2021</b> , 106, 2940-2946	6.6	4
126	Clinical features of Waldenstrom macroglobulinemia in Korea. <b>2004</b> , 19, 137-40		3
125	The current lymphoma classification: new concepts and practical applications triumphs and woes. <b>2012</b> , 32, 296-305		5
124	Treatment of Patients with Monoclonal Gammopathy of Clinical Significance. <b>2021</b> , 13,		0
123	Upper airway obstruction caused by primary lymphoplasmacytic lymphoma of the retropharyngeal space: a case report. <b>2021</b> , 37,		

- 122 Lymphoplasmozytisches Lymphom/Makroglobulinämie Waldenström. **2006**, 2928-2952
- 121 Novel Options of Therapy in Waldenström Macroglobulinemia. **2007**, 277-297
- 120 Multiple Myeloma and Related Disorders. **2008**, 2323-2351 1
- 119 [Autoimmune hemolytic anemia]. **2009**, 129, 2226-31 0
- 118 Immunoglobuline monoclonale : quand l'hématologue a-t-il besoin du neurologue ?. **2009**, 193, 1089-1097
- 117 A Case of Synchronous Double Gastric and Rectal Carcinomas Lymphoplasmacytic Lymphoma responding to Preoperative Double Filtration Plasmapheresis. **2010**, 43, 154-159
- 116 Bortezomib in Waldenström Macroglobulinemia. **2011**, 123-133
- 115 Bone marrow. **2011**, 1927-2012
- 114 Waldenström Macroglobulinemia Associated with Cryoglobulinemia: Pathogenetic, Clinical, and Therapeutic Aspects. **2012**, 277-283
- 113 Peripheral Neuropathy and Central Nervous System Involvement in Cryoglobulinemia. **2012**, 209-217
- 112 Lymph Nodes. **2012**, 905-1021
- 111 The World Health Organization Classification of Lymphoid Neoplasms. **2013**, 1-34
- 110 Lymphomes de la zone marginale. **2013**, 125-136
- 109 Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma. **2013**, 83-109
- 108 Waldenström Macroglobulinemia. **2014**, 289-300
- 107 [Case of primary lymphoplasmacytic lymphoma limited to the paratracheal mediastinum]. **2013**, 35, 213-8 0
- 106 Multiple Myeloma and Related Disorders. **2014**, 1991-2017.e7 1
- 105 Waldenström Macroglobulinemia. **2014**, 303-329

104 Signaling Pathways in Rare Lymphomas. **2014**, 71-95

103 Indolent Lymphomas: Follicular Lymphoma, HVC-Associated Marginal Zone B-Cell Lymphoma, and Waldenstrom's Macroglobulinemia. **2015**, 245-252

102 B-Cell Non-Hodgkin's Lymphomas with Lymphoplasmacytoid and Plasmacytic Features. **2016**, 1-22

101 Risk Stratification in Waldenstrom's Macroglobulinemia. **2017**, 279-293

100 B-Cell Non-Hodgkin's Lymphomas with Lymphoplasmacytoid and Plasmacytic Features. **2017**, 1637-1658

99 Lymphoplasmacytic lymphoma in the era of next generation sequencing. **2017**, 97-109

98 Hyperviscosity Syndrome Provoking Heart Failure in a Patient with Waldenstrom's macroglobulinemia. **2017**, 6,

97 6. Diagnosis and Treatment of Waldenstrom's Macroglobulinemia. **2017**, 106, 1948-1953

96 Ibrutinib for rituximab-refractory Waldenstrom's macro-globulinemia. **2018**, 9, 12536-12537

1

95 Lymphatische Neoplasien und ihre Manifestation im Knochenmark. **2019**, 141-176

94 A Case of Waldenstrom's Macroglobulinemia Morphologically Resembling Plasma Cell Myeloma. **2019**, 8, 26-28

93 Indicaciones e interpretaci3n del proteinograma. **2019**, 26, 263-270

92 Pseudothrombus deposition accompanied with minimal change nephrotic syndrome and chronic kidney disease in a patient with Waldenstrom's macroglobulinemia: A case report. **2019**, 7, 2393-2400

1

91 Waldenstrom's Macroglobulinemia: A Clinicopathological Profile and Review of Six Cases. **2020**, 41, 596-601

90 Novel Therapeutics in the Management of Waldenstrom's Macroglobulinemia. **2020**, 15-26

89 Waldenstrom's Macroglobulinemia: A case report. **2020**, 9, 1768-1771

0

88 A Case of Diffuse and Nodular Glomerulosclerosis in Waldenstrom's Macroglobulinemia. **2020**, 12, e10694

87 New Therapeutic Approaches for Waldenstrom Macroglobulinemia. **2010**, 35, 53-58

1



86	Rare case of a primary non-dural central nervous system low grade B-cell lymphoma and literature review. <b>2012</b> , 5, 89-95		12
85	Novel agents in Waldenstrom Macroglobulinemia. <b>2010</b> , 1,		
84	Waldenstrom's macroglobulinemia: Recent advances in biology and therapy. <b>2009</b> , 7, 677-81, 687-90		10
83	IgM Myeloma or Waldenstrom's Macroglobulinemia Is the Big Question?. <b>2014</b> , 9, 72-5		2
82	The Paraprotein - an Enduring Biomarker. <b>2019</b> , 40, 5-22		8
81	[The consensus of the diagnosis and treatment of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia in China (2016 version)]. <i>Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi</i> , <b>2016</b> , 37, 729-734	0.4	2
80	[Clinical analysis of dexamethasone and rituximab in combination with cyclophosphamide in the treatment of 18 patients with Waldenström macroglobulinemia]. <i>Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi</i> , <b>2018</b> , 39, 589-592	0.4	0
79	[Evaluation of clinical characteristics, MYD88(L265P) mutation, CXCR4(WHIM) mutation and prognosis in Waldenström macroglobulinemia: A single center retrospective study of 93 patients]. <i>Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi</i> , <b>2017</b> , 38, 494-498	0.4	0
78	[Clinical and biological characteristics of non-IgM lymphoplasmacytic lymphoma]. <i>Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi</i> , <b>2015</b> , 36, 493-6	0.4	0
77	Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia. <i>Blood Advances</i> , <b>2020</b> , 4, 5089-5092	7.8	4
76	[Clinical characteristics and prognosis of Waldenström's macroglobulinemia: a clinical data report from a single center]. <i>Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi</i> , <b>2020</b> , 41, 1020-1024	0.4	0
75	How to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen.. <i>Current Oncology</i> , <b>2021</b> , 28, 4611-4633	2.8	0
74	Venetoclax in Previously Treated Waldenström Macroglobulinemia. <b>2021</b> , JCO2101194		8
73	Clonal hematopoiesis is associated with increased risk of progression of asymptomatic Waldenström macroglobulinemia. <i>Blood Advances</i> , <b>2021</b> ,	7.8	1
72	Waldenström Macroglobulinemia - 2021 Update on Management and Future Directions.. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2021</b> ,	2	1
71	Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation. <b>2021</b> ,		
70	Clinicoradiopathological correlation of symptomatic focal bone marrow lesions in Waldenström Macroglobulinaemia.. <i>Leukemia and Lymphoma</i> , <b>2022</b> , 1-4	1.9	
69	A Case of Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma Associated with Nephrotic Syndrome during Hemodialysis, Treated Successfully with Tirabrutinib.. <i>Internal Medicine</i> , <b>2022</b> ,	1.1	



68	Predictors of response and survival in a large cohort of 319 Waldenström macroglobulinemia patients treated with ibrutinib monotherapy.. <i>Blood Advances</i> , <b>2021</b> ,	7.8	1
67	Successful treatment with bortezomib for refractory fever associated with myelodysplastic syndrome with underlying lymphoplasmacytic lymphoma.. <i>Clinical Case Reports (discontinued)</i> , <b>2022</b> , 10, e05372	0.7	
66	Mast cell density and its clinical relevance in Waldenström's macroglobulinemia. <i>EJHaem</i> ,	0.9	
65	Management of lytic bone disease in lymphoplasmacytic lymphoma: A case report and review of the literature.. <i>Clinical Case Reports (discontinued)</i> , <b>2021</b> , 9, e05181	0.7	1
64	Blurry Vision as a Presentation of Waldenström's Macroglobulinemia: A Case Report With Review of Current Management.. <i>Journal of Investigative Medicine High Impact Case Reports</i> , <b>2022</b> , 10, 23247096211052187	1.2	
63	Neurological complications of multiple myeloma. <b>2022</b> , 415-431		
62	Simple headache revealed a rare lymphoma: Waldenstrom macroglobulinemia with unique markers: a case report and review of the literature.. <i>Journal of the Egyptian National Cancer Institute</i> , <b>2022</b> , 34, 10	1.9	2
61	Multi-catalytic Sites Inhibition of Bcl2 Induces Expanding of Hydrophobic Groove: A New Avenue Towards Waldenström Macroglobulinemia Therapy.. <i>Protein Journal</i> , <b>2022</b> , 1	3.9	
60	Two-year outcomes of tirabrutinib monotherapy in Waldenström's macroglobulinemia.. <i>Cancer Science</i> , <b>2022</b> ,	6.9	4
59	Inflammatory Waldenström's macroglobulinaemia: A French monocentric retrospective study of 67 patients.. <i>British Journal of Haematology</i> , <b>2022</b> ,	4.5	
58	Waldenstrom macroglobulinemia and simultaneous intravascular large B-cell lymphoma: Rare transformation or unhappy coincidence?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2022</b> ,	2	
57	Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance.. <i>Diagnostics</i> , <b>2022</b> , 12,	3.8	0
56	Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and multiple myeloma. 155-183		
55	Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. 207-227		
54	WHO classification of lymphomas. 228-256		
53	DataSheet_1.pdf. <b>2020</b> ,		
52	Table_1.xlsx. <b>2020</b> ,		
51	Table_2.xlsx. <b>2020</b> ,		

50 Table\_3.xlsx. **2020**,

49 Table\_4.xlsx. **2020**,

48 Image\_1.TIF. **2020**,

47 Image\_2.TIF. **2020**,

46 Image\_3.TIF. **2020**,

45 Image\_4.TIF. **2020**,

44 Image\_5.TIF. **2020**,

43 Image\_6.TIF. **2020**,

42 Image\_7.TIF. **2020**,

41 New therapeutic approaches for Waldenstrom macroglobulinemia. **2010**, 35, 53

1

40 [Clinical characteristics and prognosis of patients with Waldenström macroglobulinemia and its comparison with the Pivotal study].. *Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi*, **2021**, 42, 993-997

0.4

39 Monoclonal antibody-based therapies for Waldenström's macroglobulinemia.. *Leukemia Research Reports*, **2022**, 17, 100324

0.6

38 The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia. *Journal of Personalized Medicine*, **2022**, 12, 676

3.6

37 Does Waldenstrom's macroglobulinemia also cause bone destruction? A rare case report.. *Journal of International Medical Research*, **2022**, 50, 3000605221096161

1.4

36 The landscape of immunoglobulin heavy chain gene repertoire and its clinical relevance in LPL/WM.. *Blood Advances*, **2022**,

7.8 0

35 An Extended Prognostic Index of the ISSWM Score Based on Thyroid Complications in Waldenström Macroglobulinemia/Lymphoplasmacytoid Lymphoma. *Frontiers in Oncology*, **2022**, 12,

5.3 0

34 MYD88 Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies. *International Journal of Molecular Sciences*, **2022**, 23, 5570

6.3 1

33 Co-binding of JQ1 and Venetoclax exhibited synergetic inhibitory effect for cancer therapy; Potential line of treatment for the Waldenström macroglobulinemia lymphoma. *Chemistry and Biodiversity*,

2.5 1

32	The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. <i>Blood</i> ,	2.2	18
31	Primary Dural Mucosa-associated Lymphoid Tissue Lymphoma Mimicking Falx Meningioma: A Case Report. <i>NMC Case Report Journal</i> , <b>2022</b> , 9, 123-128	0.6	1
30	A pilot study on dasatinib in patients with Waldenström macroglobulinemia progressing on ibrutinib. <i>EJHaem</i> ,	0.9	
29	IgM monoclonal gammopathies of clinical significance: diagnosis and management. <i>Haematologica</i> ,	6.6	0
28	Concurrent Waldenström Macroglobulinemia and Myelodysplastic Syndrome with a Sequential t(10;13)(p13;q22) Translocation. <i>Current Oncology</i> , <b>2022</b> , 29, 4587-4592	2.8	0
27	Plasma cells arise from differentiation of clonal lymphocytes and secrete IgM in Waldenström macroglobulinemia. <b>2022</b> , 25, 104856		
26	Clinicopathological features and individualized treatment of kidney involvement in B-cell lymphoproliferative disorder. 13,		0
25	Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies. <b>2022</b> , 23, 11145		0
24	Cold Agglutinin Disease: Improved Understanding of Pathogenesis Helps Define Targets for Therapy. <b>2022</b> , 3, 574-594		0
23	Diagnostics in Waldenström Macroglobulinemia: a consensus statement of the European Consortium for Waldenström Macroglobulinemia.		0
22	Evaluation of orelabrutinib monotherapy in patients with relapsed or refractory Waldenström's macroglobulinemia in a single-arm, multicenter, open-label, phase 2 study. <b>2022</b> , 101682		2
21	Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström macroglobulinaemia.		0
20	Molecular remission is an independent predictor of progression-free survival in patients with Waldenström macroglobulinemia treated with chemo-immunotherapy: Results from the FIL_BIOWM study.		0
19	Waldenström's macroglobulinemia, overview of clinical symptoms, and therapy and our experience with ibrutinib therapy. <b>2022</b> , 16, 83-102		0
18	Unusual Diagnosis of Multiple Small Bowel Masses. <b>2022</b> ,		0
17	Managing Waldenström macroglobulinemia with BTK inhibitors.		1
16	Low-grade B-cell lymphoma of the central nervous system with plasmacytic differentiation and amyloid deposition.		0
15	Diagnostics in Waldenström macroglobulinemia: a consensus statement of the European Consortium for Waldenström Macroglobulinemia.		0

14	BingNeel Syndrome: Update on Diagnosis and Treatment. <b>2022</b> , 3, 758-770	0
13	Plasma cell neoplasms and related entitiesEvolution in diagnosis and classification.	0
12	Dose reductions in patients with Waldenström macroglobulinaemia treated with ibrutinib.	2
11	Survival trends in young patients with Waldenström macroglobulinemia: Over five decades of experience.	1
10	Pharmacokinetics-Pharmacodynamics Modeling and Evaluation of Tumor Response to Bortezomib Proteasome Inhibitor in Waldenstrom Macroglobulinemia. <b>2023</b> , 46, 150-160	0
9	Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing. <b>2023</b> , 98, 750-759	0
8	Orbit. <b>2023</b> , 119-165	0
7	BeEAM Conditioning including High-Dose Bendamustine before Autologous Stem Cell Transplantation Is Safe and Effective in Patients with Waldenstrom’s Macroglobulinemia. <b>2023</b> , 12, 2378	0
6	Invasive Cutaneous Candidiasis, Autoimmune Hemolytic Anemia and Pancytopenia: A Challenging Scenario for Waldenström Macroglobulinemia in an Elderly Patient. <b>2023</b> , 11, 1007	0
5	The epidemiology of Waldenström macroglobulinemia. <b>2023</b> ,	0
4	Report of Consensus Panel 3 from the 11th International workshop on Waldenström’s Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström’s Macroglobulinemia. <b>2023</b> ,	0
3	Cytogenetic aberrations of lymphoplasmacytic lymphoma/Waldenstrom’s macroglobulinemia in Chinese patients. Publish Ahead of Print,	0
2	Case report: Circulating tumor DNA technology displays temporal and spatial heterogeneity in Waldenström macroglobulinemia during treatment with BTK inhibitors. 29,	0
1	Report of Consensus Panel 4 from the 11th International Workshop on Waldenstrom’s Macroglobulinemia on Diagnostic and Response Criteria. <b>2023</b> ,	0